BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 15805268)

  • 1. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals.
    Guan R; Tapang P; Leverson JD; Albert D; Giranda VL; Luo Y
    Cancer Res; 2005 Apr; 65(7):2698-704. PubMed ID: 15805268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polo-like kinase 1 creates the tension-sensing 3F3/2 phosphoepitope and modulates the association of spindle-checkpoint proteins at kinetochores.
    Ahonen LJ; Kallio MJ; Daum JR; Bolton M; Manke IA; Yaffe MB; Stukenberg PT; Gorbsky GJ
    Curr Biol; 2005 Jun; 15(12):1078-89. PubMed ID: 15964272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
    Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z; Wu J; Dang H; Lin H; Zheng H; Zhong D
    Cancer Lett; 2011 Apr; 303(2):92-8. PubMed ID: 21330050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
    Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
    Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of antisense RNA targeting polo-like kinase 1 on cell cycle and proliferation in A549 cells.
    Zhou Q; Bai M; Su Y
    Chin Med J (Engl); 2004 Nov; 117(11):1642-9. PubMed ID: 15569479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint.
    Lei M; Erikson RL
    Oncogene; 2008 Jun; 27(28):3935-43. PubMed ID: 18297112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1.
    Liu X; Zhou T; Kuriyama R; Erikson RL
    J Cell Sci; 2004 Jul; 117(Pt 15):3233-46. PubMed ID: 15199097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibition of polo like kinase gene expression induces apoptosis in gastric cancer cells].
    Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Zhu ZG
    Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Jan; 9(1):62-6. PubMed ID: 16437376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase 1 regulates mitotic arrest after UV irradiation through dephosphorylation of p53 and inducing p53 degradation.
    Chen J; Dai G; Wang YQ; Wang S; Pan FY; Xue B; Zhao DH; Li CJ
    FEBS Lett; 2006 Jun; 580(15):3624-30. PubMed ID: 16753148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of antitumor immunity using dendritic cells electroporated with Polo-like kinase 1 (Plk1) mRNA in murine tumor models.
    Park JS; Sohn HJ; Park GS; Chung YJ; Kim TG
    Cancer Sci; 2011 Aug; 102(8):1448-54. PubMed ID: 21545375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normal cells, but not cancer cells, survive severe Plk1 depletion.
    Liu X; Lei M; Erikson RL
    Mol Cell Biol; 2006 Mar; 26(6):2093-108. PubMed ID: 16507989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tetraploidy through loss of p53 and upregulation of Plk1 by human papillomavirus type-16 E6.
    Incassati A; Patel D; McCance DJ
    Oncogene; 2006 Apr; 25(17):2444-51. PubMed ID: 16369493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
    Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
    Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic effect of Polo-like kinase 1 expression in human gastric carcinomas.
    Jang YJ; Kim YS; Kim WH
    Int J Oncol; 2006 Sep; 29(3):589-94. PubMed ID: 16865274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
    Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.